Abstract Library

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#824 Metachronous Functioning Syndromes in Sporadic Pancreatic Neuroendocrine Tumors (PNET)

Introduction: A metachronous functioning syndrome (MFS) may develop during the evolution of PNET initially functioning or not.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: de Mestier L

Authors: De Mestier L, Hentic O, Cros J, Brixi H, Walter T,

Keywords: neuroendocrine tumors, pancreas, functioning syndrome, natural evolution,

#58 Surgical approaches in 84 patients with insulinomas in multiple endocrine neoplasia type 1 (MEN 1)

Introduction: Management of insulinomas in the setting of Multiple Endocrine Neoplasia type 1 (MEN1) remains controversial.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Baudin E

Authors: Vezzosi D, Cardot-Bauters C, Murat A, Bertholon-Gregoire M, Niccoli P,

Keywords: insulinoma, multiple endocrine neoplasia type 1, enucleation, cephalic duodenopancreatectomy, splenopancreatectomy, total pancreatectomy,